[go: up one dir, main page]

NO2017012I1 - HPV 45 L1 protein - Google Patents

HPV 45 L1 protein

Info

Publication number
NO2017012I1
NO2017012I1 NO2017012C NO2017012C NO2017012I1 NO 2017012 I1 NO2017012 I1 NO 2017012I1 NO 2017012 C NO2017012 C NO 2017012C NO 2017012 C NO2017012 C NO 2017012C NO 2017012 I1 NO2017012 I1 NO 2017012I1
Authority
NO
Norway
Prior art keywords
hpv
protein
Prior art date
Application number
NO2017012C
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NO2017012I1 publication Critical patent/NO2017012I1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO2017012C 2003-09-29 2017-04-05 HPV 45 L1 protein NO2017012I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
PCT/US2004/031326 WO2005032586A1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast

Publications (1)

Publication Number Publication Date
NO2017012I1 true NO2017012I1 (no) 2017-04-05

Family

ID=34421558

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20061876A NO339932B1 (no) 2003-09-29 2006-04-28 Nukleinsyremolekyl som koder for et HPV45-L1-protein, vektor som omfatter nukleinsyremolekylet, vertscelle som omfatter vektoren, samt en fremgangsmåte for fremstilling av HPV45-L1-viruslignende partikler (VLPer) i gjær og en fremgangsmåte for å fremstille en vaksine for behandling eller forebygging av HPV infeksjoner.
NO2017012C NO2017012I1 (no) 2003-09-29 2017-04-05 HPV 45 L1 protein
NO2022051C NO2022051I1 (no) 2003-09-29 2022-11-30 HPV 45L1 protein - forlengelse SPC

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20061876A NO339932B1 (no) 2003-09-29 2006-04-28 Nukleinsyremolekyl som koder for et HPV45-L1-protein, vektor som omfatter nukleinsyremolekylet, vertscelle som omfatter vektoren, samt en fremgangsmåte for fremstilling av HPV45-L1-viruslignende partikler (VLPer) i gjær og en fremgangsmåte for å fremstille en vaksine for behandling eller forebygging av HPV infeksjoner.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2022051C NO2022051I1 (no) 2003-09-29 2022-11-30 HPV 45L1 protein - forlengelse SPC

Country Status (33)

Country Link
US (2) US7250170B2 (no)
EP (1) EP1673106B1 (no)
JP (4) JP5451960B2 (no)
KR (1) KR101165278B1 (no)
CN (1) CN1859923B (no)
AR (2) AR045804A1 (no)
AT (1) ATE435029T1 (no)
AU (1) AU2004277934B2 (no)
BE (1) BE2015C072I2 (no)
BR (1) BRPI0414845B8 (no)
CA (1) CA2539168C (no)
CY (2) CY1110525T1 (no)
DE (1) DE602004021828D1 (no)
DK (1) DK1673106T3 (no)
ES (1) ES2327530T3 (no)
FR (1) FR15C0083I2 (no)
HU (1) HUS1500063I1 (no)
IL (1) IL174458A (no)
IS (1) IS2694B (no)
LT (2) LTPA2015049I1 (no)
LU (1) LU92902I2 (no)
MX (1) MXPA06003457A (no)
MY (1) MY140664A (no)
NL (1) NL300776I2 (no)
NO (3) NO339932B1 (no)
NZ (1) NZ545834A (no)
PL (1) PL1673106T3 (no)
PT (1) PT1673106E (no)
RU (1) RU2360001C2 (no)
SI (1) SI1673106T1 (no)
TW (1) TWI350853B (no)
WO (1) WO2005032586A1 (no)
ZA (1) ZA200601961B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
MY148656A (en) 2004-03-24 2013-05-15 Merck Sharp & Dohme Optimized expression of hpv 52 l1 in yeast.
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
EA013326B1 (ru) * 2005-04-26 2010-04-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
US8101342B2 (en) * 2006-08-28 2012-01-24 Sungkyunkwan University Foundation For Corporate Collaboration DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein
JP2010520874A (ja) * 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
MX2010005699A (es) 2007-11-23 2010-09-14 Shanghai Zerun Biotechnology C Genes que codifican para la proteina l1 mayor de la capside del virus del papiloma humano y uso de los mismos.
MX2011013566A (es) 2009-06-19 2012-06-28 Eyegene Inc Vacunas para cancer cervical.
EP2576840B1 (en) 2010-05-25 2018-10-17 QIAGEN Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
AU2012270418B2 (en) 2011-06-15 2015-08-13 Posvax Co., Ltd Method for enhancing the production yield of human papillomavirus L1 protein
RU2610174C2 (ru) 2011-06-24 2017-02-08 Мерк Шарп И Доум Корп. Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN108624614A (zh) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN104120088B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104164447B (zh) * 2013-05-17 2019-08-13 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN112280792B (zh) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 人乳头瘤病毒基因,及载体,菌株,表达方法
WO2015057541A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
EP3191505A2 (en) * 2014-09-11 2017-07-19 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
AR121292A1 (es) 2020-02-14 2022-05-04 Merck Sharp & Dohme Vacuna contra hpv
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
WO2023014853A1 (en) 2021-08-06 2023-02-09 Merck Sharp & Dohme Llc Hpv vaccine
JP2024532127A (ja) 2021-08-19 2024-09-05 メルク・シャープ・アンド・ドーム・エルエルシー 熱安定性脂質ナノ粒子およびその使用方法
WO2024254226A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1152935A (zh) * 1994-05-16 1997-06-25 麦克公司 乳头状瘤病毒疫苗
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
PL335050A1 (en) 1997-02-07 2000-03-27 Merck & Co Inc Synthetic genes gag hiv
DE69732378D1 (de) * 1997-05-27 2005-03-03 Hanil Synthetic Fiber Co Ltd Verfahren zur herstellung von rekombinanten eiweissen durch verwendung von hocheffizienten expressionsvektoren aus saccharomyces cerevisiae
JP4434479B2 (ja) 1997-07-09 2010-03-17 ザ・ユニバーシティ・オブ・クイーンズランド 標的の細胞および組織においてタンパク質を選択的に発現するための核酸配列および方法
EP1105157B1 (en) * 1998-08-14 2006-11-02 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
SK2232001A3 (en) * 1998-08-14 2001-08-06 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
ES2237204T3 (es) * 1998-12-23 2005-07-16 MERCK & CO., INC. Ensayo de neutralizacion usando particulas similares al virus de papilomavirus humano.
ES2233437T3 (es) 1999-08-25 2005-06-16 MERCK & CO., INC. Genes sinteticos del papilomavirus optimizados para expresion en celulas humanas.
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
IL154009A0 (en) 2000-07-21 2003-07-31 Glaxo Group Ltd Codon-optimized papilloma virus sequences
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
JP4505452B2 (ja) 2003-03-24 2010-07-21 メルク・シャープ・エンド・ドーム・コーポレイション 酵母におけるhpv31l1の最適化発現

Also Published As

Publication number Publication date
KR101165278B1 (ko) 2012-07-23
CY2015050I1 (el) 2016-06-22
US7482015B2 (en) 2009-01-27
IS2694B (is) 2010-11-15
KR20070029628A (ko) 2007-03-14
MXPA06003457A (es) 2006-06-05
RU2360001C2 (ru) 2009-06-27
ES2327530T3 (es) 2009-10-30
CA2539168C (en) 2011-05-31
MY140664A (en) 2010-01-15
ZA200601961B (en) 2007-05-30
NL300776I1 (no) 2015-12-29
AU2004277934A1 (en) 2005-04-14
IL174458A0 (en) 2006-08-01
WO2005032586A1 (en) 2005-04-14
JP2016136947A (ja) 2016-08-04
EP1673106A1 (en) 2006-06-28
DK1673106T3 (da) 2009-11-09
NO339932B1 (no) 2017-02-20
PL1673106T3 (pl) 2009-12-31
CA2539168A1 (en) 2005-04-14
SI1673106T1 (sl) 2009-12-31
CN1859923B (zh) 2012-09-05
CY1110525T1 (el) 2015-04-29
PT1673106E (pt) 2009-09-22
NZ545834A (en) 2009-02-28
CN1859923A (zh) 2006-11-08
TW200521233A (en) 2005-07-01
JP5451960B2 (ja) 2014-03-26
NO20061876L (no) 2006-04-28
JP2007507207A (ja) 2007-03-29
FR15C0083I2 (fr) 2016-11-25
LU92902I2 (fr) 2016-03-08
RU2006114701A (ru) 2007-11-10
BRPI0414845B1 (pt) 2020-10-13
LTC1673106I2 (lt) 2017-05-10
JP2011152137A (ja) 2011-08-11
US20080138361A1 (en) 2008-06-12
BE2015C072I2 (no) 2023-12-14
IL174458A (en) 2014-06-30
IS8362A (is) 2006-03-20
HUS1500063I1 (hu) 2016-02-29
AR045804A1 (es) 2005-11-16
AR077396A2 (es) 2011-08-24
CY2015050I2 (el) 2016-06-22
AU2004277934B2 (en) 2009-09-17
JP2014221052A (ja) 2014-11-27
NL300776I2 (no) 2015-12-29
FR15C0083I1 (fr) 2016-08-01
BRPI0414845B8 (pt) 2021-06-15
US7250170B2 (en) 2007-07-31
TWI350853B (en) 2011-10-21
ATE435029T1 (de) 2009-07-15
DE602004021828D1 (de) 2009-08-13
EP1673106B1 (en) 2009-07-01
US20060240040A1 (en) 2006-10-26
LTPA2015049I1 (lt) 2016-01-11
BRPI0414845A (pt) 2006-11-21
NO2022051I1 (no) 2022-11-30

Similar Documents

Publication Publication Date Title
NO2017058I1 (no) HPV 58 L1 protein
NO2017012I1 (no) HPV 45 L1 protein
EP1642377A4 (en) VIBRATION DEVICE
DE60330207D1 (de) le
NO20052802D0 (no) Pyrrolopyrimidinderivativer
DK1689775T3 (da) GAG-bindende proteiner
DK1663936T3 (da) Biaryloxymethylaren-carboxylsyrer
ATE318817T1 (de) Aza-arylpiperazine
ATE349458T1 (de) Etonogestrelester
NO20034452L (no) Sykdoms-assosiert protein
DE50312759D1 (de) Oszillationsantrieb
ATA1572002A (de) Managementspleisskassette
DE50313381D1 (de) Oszillationsantrieb
BR0311793B1 (pt) Projétil de neblina
ATA4142004A (de) Trägerverbau
DE50309081D1 (de) Neue diketopyrrolopyrrolpigmente
ATA19152002A (de) Hubkupplung
EP1515991A4 (en) MOLECULES SIGNING PAIN
DE50300379D1 (de) Oszillationsantrieb
NO20053512D0 (no) IL-8-liknende proteiner
NO20050436D0 (no) Beta-lagnedbrytende peptider
NO20052608D0 (no) Midkinlignende protein
AT5889U3 (de) Brennholzspleisser
ATA16872002A (de) Zwischenstück
ATA522002A (de) Vmp-bindungsprotein